Malignant Neoplasm of the Pancreas (ICD-11: 2C10) - Complete Clinical Coding Guide

1. Introduction

Malignant neoplasm of the pancreas represents one of the most significant challenges in modern oncology, characterized by its aggressive nature and frequently unfavorable prognosis. This type of cancer originates from pancreatic cells, with pancreatic ductal adenocarcinoma responsible for the vast majority of cases, representing approximately 90% of all primary malignant tumors of the pancreas.

The clinical importance of this condition is substantial, considering that pancreatic cancer ranks among the leading causes of cancer death worldwide. The disease presents particularly challenging characteristics: nonspecific or absent initial symptoms, frequently late diagnosis, rapid progression, and limited therapeutic options in advanced stages. The five-year survival rate remains considerably low compared to other types of cancer, making this neoplasm a priority in oncology research and public health.

From an epidemiological perspective, there is a gradual increase in the global incidence of this neoplasm, associated with population aging and the prevalence of modifiable risk factors such as smoking, obesity, and diabetes mellitus. The impact on public health is significant, not only due to elevated mortality, but also due to substantial healthcare costs related to diagnosis, treatment, and palliative care.

Correct coding using ICD-11 is absolutely critical for multiple purposes: precise epidemiological surveillance, adequate resource allocation, health policy planning, clinical research, procedure reimbursement, and outcome monitoring. Precision in coding allows reliable international comparisons and contributes to advancing knowledge about this devastating disease.

2. Correct ICD-11 Code

Code: 2C10

Description: Malignant neoplasm of the pancreas

Parent category: Malignant neoplasms of digestive organs

Official definition: Primary malignant tumor of the pancreas. Most are adenocarcinomas.

The code 2C10 in the ICD-11 system specifically represents primary malignant neoplasms that originate in pancreatic tissue. This code encompasses all histological types of primary pancreatic cancer, although ductal adenocarcinoma is the predominant histological type. The classification includes tumors originating from both the exocrine and endocrine portions of the pancreas, provided they are of primary malignant nature.

It is fundamental to understand that this code applies exclusively to primary malignant tumors, that is, those that originate in the pancreas itself, differentiating from pancreatic metastases from other organs or mesenchymal neoplasms that may affect the organ. The hierarchical structure of ICD-11 allows greater specificity through subcategories, enabling additional detail regarding specific anatomical location within the pancreas (head, body, tail) or histological type, when relevant for clinical or epidemiological purposes.

Appropriate coding with 2C10 facilitates communication among healthcare professionals, ensures internationally standardized medical records, and enables robust statistical analyses on incidence, prevalence, survival, and treatment effectiveness for this specific condition.

3. When to Use This Code

The code 2C10 should be used in specific clinical situations where there is confirmation of primary malignant neoplasm of the pancreas. Below are detailed practical scenarios:

Scenario 1: Pancreatic ductal adenocarcinoma confirmed by biopsy A 65-year-old patient presents with progressive jaundice, weight loss of 10 kg in two months, and epigastric pain. Computed tomography identifies a mass in the pancreatic head measuring 4 cm in diameter. Biopsy guided by endoscopic ultrasound confirms ductal adenocarcinoma. In this case, 2C10 is the appropriate code, as there is histopathological confirmation of primary malignant neoplasm of the pancreas.

Scenario 2: Malignant pancreatic neuroendocrine tumor Patient diagnosed with functional neuroendocrine tumor of the pancreas, with evidence of vascular invasion and hepatic metastases. Although neuroendocrine tumors have distinct biological behavior from adenocarcinomas, when malignant and originating in the pancreas, they are also coded under 2C10, and subcategories may be used to specify the histological type.

Scenario 3: Acinar cell carcinoma Patient with solid tumor in the pancreatic body, confirmed histologically as acinar cell carcinoma, a rare type of exocrine pancreatic malignant neoplasm. This specific histological type also falls under code 2C10, representing a primary malignant neoplasm of the pancreas.

Scenario 4: Mucinous cystadenocarcinoma Identification of cystic lesion in the pancreas with characteristics of malignancy, confirmed surgically and histologically as mucinous cystadenocarcinoma. This malignant variant of pancreatic cystic tumor is appropriately coded with 2C10.

Scenario 5: Local recurrence after surgical resection Patient previously submitted to pancreaticoduodenectomy for pancreatic adenocarcinoma, now presenting with local recurrence confirmed by biopsy. The code 2C10 remains appropriate, and specifiers may be added to indicate recurrence or disease progression.

Scenario 6: Intraoperative diagnosis During exploratory laparotomy, a pancreatic tumor is identified with macroscopic characteristics of malignancy, confirmed by intraoperative frozen section biopsy. Even with preliminary histological confirmation, code 2C10 is applicable, and should be confirmed later with the definitive anatomopathological examination.

4. When NOT to Use This Code

It is essential to recognize situations where code 2C10 should not be applied, avoiding coding errors that may compromise medical records and health statistics.

Pancreatic metastases from other primary tumors: When the pancreas is affected by metastases from tumors originating in other organs (such as lung, breast, kidney, or melanoma), code 2C10 should not be used. In these cases, the original primary tumor is coded and a specific code for pancreatic metastasis is added.

Mesenchymal neoplasms of the pancreas: Tumors of mesenchymal origin affecting the pancreas, such as sarcomas, gastrointestinal stromal tumors (GIST), or leiomyosarcomas, should be coded with a specific code for mesenchymal neoplasms (code 1965082709), and not with 2C10, which is reserved for primary epithelial neoplasms.

Pancreatic lymphomas: Although rare, lymphomas may affect the pancreas primarily or secondarily. These hematologic neoplasms should be coded with specific codes for lymphomas, not using 2C10.

Premalignant lesions or intraepithelial neoplasias: Lesions such as pancreatic intraepithelial neoplasia (PanIN) or intraductal papillary mucinous neoplasms (IPMN) without confirmation of malignant invasion should not be coded as 2C10. These lesions have specific codes for neoplasms of uncertain or premalignant behavior.

Benign tumors of the pancreas: Benign lesions such as serous cystadenomas, pseudocysts, or benign insulinomas should not receive code 2C10, which is exclusive for malignant neoplasms.

Chronic pancreatitis with inflammatory mass: Pancreatic masses resulting from chronic pancreatitis, even when mimicking neoplasms on imaging studies, should not be coded as 2C10 in the absence of histopathologic confirmation of malignancy.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The first fundamental step is to confirm the diagnosis of malignant pancreatic neoplasm through objective criteria. Histopathological confirmation is the gold standard, obtained through image-guided percutaneous biopsy, endoscopic ultrasound biopsy, or analysis of surgical specimen. Cytopathological evaluation of fine needle aspiration can also be used, although histological confirmation is preferable.

Imaging studies are essential in initial evaluation: multiphase computed tomography with pancreatic protocol provides information about lesion characteristics, relationship with vascular structures, and presence of metastases. Magnetic resonance imaging can offer additional details, especially for cystic lesions. Endoscopic ultrasound allows detailed evaluation of small lesions and facilitates obtaining material for histopathological analysis.

Tumor markers, particularly CA 19-9, although not diagnostic in isolation, assist in complementary evaluation and monitoring. Significantly elevated values in appropriate clinical and radiological context strengthen diagnostic suspicion.

Step 2: Verify specifiers

After confirming the diagnosis, it is important to identify relevant specifiers that can be added to code 2C10 for greater precision. These include:

Anatomical location: Specify whether the tumor is in the head, body, or tail of the pancreas, or if it is multifocal. This information is clinically relevant as it influences surgical approach and prognosis.

Histological type: Although ductal adenocarcinoma is the most common, other types such as acinar cell carcinoma, cystadenocarcinoma, adenosquamous carcinoma, or malignant neuroendocrine tumors can be specified.

Staging: Information about local extension (T), lymph node involvement (N), and presence of metastases (M) are crucial for therapeutic planning and prognosis.

Degree of differentiation: Histological classification into well differentiated, moderately differentiated, or poorly differentiated provides important prognostic information.

Step 3: Differentiate from other codes

2B70 - Malignant neoplasms of esophagus: Clearly differs from 2C10 by anatomical location. Esophageal tumors originate in the upper digestive tract, present with symptoms such as dysphagia and odynophagia, and are diagnosed by upper endoscopy. There is no anatomical overlap with the pancreas.

2B71 - Malignant neoplasms of esophagogastric junction: This code refers specifically to tumors at the transition between esophagus and stomach (cardia). The differentiation from 2C10 is anatomical and clear on imaging and endoscopy. There is no relationship with the pancreas, although both are organs of the digestive system.

2B72 - Malignant neoplasms of stomach: Gastric tumors originate in the gastric mucosa and are diagnosed by upper endoscopy with biopsy. Although the pancreas is anatomically close to the stomach, differentiation is clear through imaging methods. Occasionally, advanced pancreatic tumors may invade the gastric wall, but the appropriate code remains 2C10 if the primary tumor is pancreatic.

Step 4: Required documentation

For appropriate coding with 2C10, medical documentation must include:

Mandatory checklist:

Histopathological or cytopathological confirmation of malignancy
Imaging study report describing tumor location and characteristics
Specific histological type when available
Clinical or pathological staging (TNM)
Date of initial diagnosis
Method of diagnosis obtainment (biopsy, surgery, cytology)
Tumor markers when performed
Assessment of surgical resectability
Presence or absence of distant metastases
Proposed therapeutic plan

This complete documentation ensures accurate coding, facilitates continuity of care, allows for appropriate audits, and contributes to reliable epidemiological records.

6. Complete Practical Example

Clinical Case

A 68-year-old male patient, previously healthy, seeks medical care reporting a three-month history characterized by unintentional weight loss of 12 kg, progressive asthenia, and vague epigastric discomfort. Over the past two weeks, he developed progressive jaundice with dark urine and acholic stools. He denies fever but reports generalized pruritus. History of 40 pack-years of smoking, ceased 5 years ago. Father deceased from pancreatic cancer at age 70.

On physical examination, he presents with jaundice (3+/4+), cachexia, with palpable gallbladder (positive Courvoisier sign), without other palpable abdominal masses. Laboratory tests reveal total bilirubin of 15 mg/dL (predominantly direct), significantly elevated alkaline phosphatase and gamma-GT, mildly increased transaminases. CA 19-9 returns with a value of 850 U/mL.

Abdominal ultrasound demonstrates dilation of intra- and extra-hepatic bile ducts, distended gallbladder, and heterogeneous mass at the head of the pancreas. Multiphase computed tomography confirms a solid hypovascular mass of 3.5 cm in the pancreatic head, partially involving the superior mesenteric vein, with dilation of the main pancreatic duct and bile duct. No evidence of hepatic or pulmonary metastases. Slightly enlarged peripancreatic lymph nodes.

Endoscopic ultrasound performed for better characterization and tissue diagnosis demonstrates an irregular hypoechoic mass in the pancreatic head. Fine-needle aspiration is performed, and cytopathological analysis confirms neoplastic cells compatible with adenocarcinoma.

Multidisciplinary evaluation concludes this is locally advanced borderline resectable adenocarcinoma of the pancreatic head. Neoadjuvant chemotherapy followed by surgical re-evaluation is proposed.

Coding Step by Step

Analysis of criteria:

Diagnostic confirmation: There is cytopathological confirmation of adenocarcinoma through endoscopic ultrasound-guided aspiration, satisfying the fundamental criterion for coding as malignant neoplasm.
Primary location: Imaging studies (ultrasound, computed tomography, and endosonography) converge on pancreatic origin of the neoplasm, specifically in the head of the organ. There is no evidence of primary tumor in another location.
Histological type: Adenocarcinoma, the most common histological type of pancreatic malignant neoplasm, confirmed by cytopathological analysis.
Exclusion of differential diagnoses: This is not pancreatic metastasis (absence of another primary tumor), is not mesenchymal neoplasm (adenocarcinoma confirmed), is not benign or pre-malignant lesion (malignancy confirmed).

Code selected: 2C10 - Malignant neoplasm of pancreas

Complete justification:

Code 2C10 is appropriate because all essential criteria are satisfied: primary malignant tumor (adenocarcinoma) originating in the pancreas, histologically confirmed, with no evidence that it is metastasis or neoplasm of another nature. The location in the pancreatic head can be specified through subcategory when the coding system used allows for greater detail.

Applicable complementary codes:

Code for specific TNM staging (when available in the system)
Code for obstructive jaundice as clinical manifestation
Code for family history of pancreatic cancer (relevant risk factor)
Code for smoking (history) as risk factor
Code for endoscopic ultrasound-guided biopsy procedure

This complete coding allows adequate recording of the principal condition, related factors, and procedures performed, facilitating epidemiological analysis, therapeutic planning, and continuity of care.

7. Related Codes and Differentiation

Within the Same Category

2B70: Malignant neoplasms of esophagus

When to use 2B70: This code applies to primary malignant tumors originating in the esophagus, whether in the upper, middle, or lower third. Characteristic symptoms include progressive dysphagia (initially for solids, later for liquids), odynophagia, and weight loss. Diagnosis is established by upper endoscopy with biopsy.

Main difference vs. 2C10: The fundamental differentiation is anatomical. The esophagus is a tubular organ connecting the pharynx to the stomach, whereas the pancreas is a solid retroperitoneal organ. There is no anatomical overlap. Diagnostic methods also differ: the esophagus is evaluated primarily by endoscopy, while the pancreas requires cross-sectional imaging methods and frequently endoscopic ultrasound for biopsy.

2B71: Malignant neoplasms of esophagogastric junction

When to use 2B71: Specific code for tumors originating at the esophagogastric transition (cardia), an anatomically defined region where the esophagus meets the stomach. These tumors present particular clinical and epidemiological characteristics, with increasing incidence in recent decades.

Main difference vs. 2C10: Again, the differentiation is anatomical. The esophagogastric junction is a specific region of the upper digestive tract, with no direct anatomical relationship to the pancreas. Although advanced pancreatic tumors may invade adjacent structures, including the stomach, the appropriate code is determined by the site of primary tumor origin.

2B72: Malignant neoplasms of stomach

When to use 2B72: Applies to malignant tumors originating in the gastric mucosa, in any of the anatomical regions of the stomach (fundus, body, antrum, pylorus). Gastric adenocarcinoma is the most common histological type, but gastric lymphomas also occur.

Main difference vs. 2C10: The differentiation is based on the organ of origin. Gastric tumors originate from the gastric mucosa and are diagnosed by upper endoscopy. Pancreatic tumors originate from the pancreatic parenchyma. In cases of locally advanced tumors with invasion of adjacent structures, the primary origin determines the principal code. Cross-sectional imaging (computed tomography, magnetic resonance imaging) is fundamental to establish the primary site when there is doubt.

Differential Diagnoses

Chronic pancreatitis: Can mimic pancreatic neoplasia clinically and radiologically. Differentiation requires clinical correlation (history of alcohol use, recurrent episodes of acute pancreatitis), tumor markers (usually normal in pancreatitis), and frequently histopathological confirmation.

Pancreatic metastases: The pancreas can be affected by metastases from renal tumors, lung tumors, melanoma, or others. History of prior neoplasia and radiological characteristics (multiple, well-demarcated lesions) suggest metastasis. Histological confirmation is essential.

Pancreatic neuroendocrine tumors: Although also coded under 2C10 when malignant, they present distinct biological behavior, with generally better prognosis. They may be functioning (producing hormones) or non-functioning.

8. Differences with ICD-10

In the ICD-10 system, malignant neoplasm of the pancreas was coded with code C25, with subdivisions to specify anatomical location:

C25.0: Head of pancreas
C25.1: Body of pancreas
C25.2: Tail of pancreas
C25.3: Pancreatic duct
C25.4: Islet cells of pancreas
C25.7: Other parts of pancreas
C25.8: Overlapping lesion of pancreas
C25.9: Pancreas, unspecified

The transition to ICD-11 with code 2C10 brings important structural changes:

Main changes: ICD-11 adopts a different alphanumeric structure, with greater flexibility for post-coordinated specifiers. While ICD-10 used fixed subdivisions in the fourth character, ICD-11 allows adding details through extension axes, including anatomical location, histology, staging, and other relevant characteristics.

The hierarchical organization is more logical and intuitive in ICD-11, facilitating navigation and coding. The possibility of multiple specifiers allows more precise documentation without excessive code proliferation.

Practical impact: Healthcare professionals and coders need to familiarize themselves with the new structure. Health information systems require updating to accommodate the new format. Historical data comparability requires conversion tables between ICD-10 and ICD-11.

The greater potential specificity of ICD-11 can improve cancer registries, epidemiological research, and outcome monitoring, provided that professionals properly use the available specifiers. The transition represents an opportunity to improve the quality of health information related to pancreatic neoplasms.

9. Frequently Asked Questions

1. How is malignant neoplasm of the pancreas diagnosed?

Diagnosis requires a combination of clinical evaluation, laboratory tests, imaging methods, and histopathological confirmation. Clinically, suspicion arises in patients with obstructive jaundice, unexplained weight loss, epigastric pain, or recently onset diabetes. Tumor markers such as CA 19-9 aid in evaluation, but are not diagnostic in isolation. Computed tomography with pancreatic protocol is the preferred initial imaging examination, frequently followed by endoscopic ultrasound which allows detailed visualization and obtainment of material for biopsy. Histopathological confirmation through biopsy is essential before initiating treatment, except in specific situations where clinical and radiological characteristics are unequivocal and biopsy represents disproportionate risk.

2. Is treatment available in public health systems?

Treatment for malignant neoplasm of the pancreas is generally available in public health systems, although availability of specific modalities may vary among different regions and institutions. Treatment may include surgery (pancreaticoduodenectomy or distal resections), chemotherapy, radiotherapy, or combinations of these modalities. Complex surgeries such as pancreaticoduodenectomy (Whipple surgery) require specialized centers with experience in hepatopancreatic surgery. Chemotherapy with modern regimens and targeted therapies may have variable availability depending on local protocols and regulatory approvals. Palliative care, including pain control and symptom management, should be universally available.

3. How long does treatment last?

Treatment duration varies substantially depending on disease staging and the chosen therapeutic strategy. For resectable disease, surgical treatment is a single event, but frequently followed by adjuvant chemotherapy for approximately six months. In borderline resectable or locally advanced disease, neoadjuvant chemotherapy may last three to six months before surgical re-evaluation. For metastatic disease, palliative chemotherapy may be maintained for prolonged periods as long as there is benefit and adequate tolerability, frequently for several months. Follow-up after curative treatment extends for years, with periodic surveillance through imaging studies and tumor markers.

4. Can this code be used in medical certificates?

Yes, code 2C10 can and should be used in medical certificates when appropriate, especially in documentation for purposes of work leave, disability benefit requests, or justification of absences. However, it is important to consider issues of patient confidentiality and privacy. In some situations, it may be preferable to use more generic terms in documents that do not require extreme diagnostic specificity. For complete medical documentation, hospital records, reports for other healthcare professionals, and epidemiological registries, the specific code 2C10 should always be used to ensure accuracy and continuity of care.

5. Does malignant neoplasm of the pancreas always have a poor prognosis?

Although pancreatic cancer generally presents a challenging prognosis, there is significant variability depending on multiple factors. Tumors diagnosed at early stages and completely resected surgically have substantially better prognosis, with five-year survival rates potentially reaching 20-40% in selected cases. Pancreatic neuroendocrine tumors, even when malignant, frequently present more indolent evolution and more favorable prognosis than ductal adenocarcinomas. Recent advances in chemotherapy and identification of molecular subgroups that respond to specific therapies are gradually improving outcomes. Individual prognosis depends on staging, histological type, degree of differentiation, treatment response, and molecular characteristics of the tumor.

6. What is the difference between pancreatic tumor and pancreatitis?

Pancreatitis is an inflammatory process of the pancreas, which can be acute or chronic, generally related to gallstones, excessive alcohol consumption, or other causes. It is not cancer, although chronic pancreatitis is a risk factor for future development of pancreatic neoplasia. Pancreatic tumor refers to neoplastic growth, which can be benign or malignant. Differentiation is fundamental but sometimes challenging, as chronic pancreatitis can form inflammatory masses that mimic tumors. Advanced imaging studies, tumor markers, and frequently biopsy are necessary for definitive differentiation. Both conditions can cause similar symptoms such as abdominal pain and weight loss, but treatment and prognosis are completely different.

7. Is it possible to prevent pancreatic cancer?

There is no absolute prevention, but modification of risk factors can reduce the probability of development. Smoking cessation is the most important preventive measure, as smoking is a well-established risk factor. Maintenance of healthy weight, regular physical activity, and balanced diet can contribute to risk reduction. Adequate diabetes control and avoiding excessive alcohol consumption are also recommended. For individuals with increased risk (strong family history, specific genetic syndromes, hereditary chronic pancreatitis), surveillance programs with periodic examinations may be appropriate, although the effectiveness of this approach is still being studied. Consultation with a specialist is recommended for individualized risk assessment.

8. Are tumor markers sufficient for diagnosis?

No. Tumor markers such as CA 19-9 are valuable auxiliary tools, but do not replace histopathological confirmation. CA 19-9 may be elevated in pancreatic neoplasia, but also in benign conditions such as pancreatitis, cholangitis, cirrhosis, or biliary obstruction. Approximately 10% of the population does not express the CA 19-9 antigen due to specific genetic characteristics, resulting in normal values even in the presence of cancer. CA 19-9 values are useful for monitoring treatment response and detecting recurrence in patients with established diagnosis, but initial diagnosis always requires confirmation through biopsy or, in selected situations, unequivocal combination of clinical and radiological findings. Tumor markers should be interpreted in the complete clinical context, never in isolation.

Conclusion:

Appropriate coding of malignant neoplasm of the pancreas using ICD-11 code 2C10 is fundamental for accurate documentation, effective communication among healthcare professionals, epidemiological surveillance, and clinical research. This guide provides practical guidance for correct code application, differentiation of similar conditions, and understanding of essential diagnostic criteria. The complexity of this condition requires a multidisciplinary approach, accurate diagnosis, and careful coding to optimize patient care and contribute to advancement of knowledge about this challenging disease.

External References

This article was prepared based on reliable scientific sources:

🌍 WHO ICD-11 - Malignant neoplasm of pancreas
🔬 PubMed Research on Malignant neoplasm of pancreas
🌍 WHO Health Topics
📊 Clinical Evidence: Malignant neoplasm of pancreas
📋 Ministry of Health - Brazil
📊 Cochrane Systematic Reviews

References verified on 2026-02-04

Malignant neoplasm of the pancreas

Partager